menu
Intellia Therapeutics Head office building

Press Releases

Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2023 Earnings and Company Updates

CAMBRIDGE, Mass. , April 27, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, will present its first quarter 2023 financial results and
Read More

Intellia Therapeutics Names Bill Chase to its Board of Directors

CAMBRIDGE, Mass. , April 17, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today announced the appointment of Bill Chase , MBA, to its
Read More

Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to NTLA-2002 for the Treatment of Hereditary Angioedema

CAMBRIDGE, Mass. , March 21, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today announced that the U.S.
Read More

Intellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for NTLA-2002, an In Vivo CRISPR-Based Investigational Therapy for the Treatment of Hereditary Angioedema (HAE)

NTLA-2002 is a single dose, in vivo genome editing candidate designed to prevent potentially life-threatening swelling attacks in people with HAE CAMBRIDGE, Mass. , March 02, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused
Read More

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2022 Financial Results and Highlights Recent Company Progress

Initiated the global Phase 2 study of NTLA-2002, a CRISPR-based, potential single-dose treatment for hereditary angioedema (HAE) Submitted IND application for NTLA-2002 to enable patient enrollment in the U.S. for the Phase 2 study Plans to submit IND application in mid-2023 for global pivotal
Read More

Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2022 Earnings and Company Updates

CAMBRIDGE, Mass. , Feb. 16, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, will present its fourth quarter and full-year 2022 financial
Read More

Intellia Therapeutics Awarded Innovation Passport in the United Kingdom for NTLA-2002, an Investigational Genome Editing Treatment for Hereditary Angioedema

Innovation Passport provides entry to the U.K.’s Innovative Licensing and Access Pathway (ILAP), which aims to accelerate time to market and facilitate patient access to innovative medicines NTLA-2002 is a single-dose genome editing therapeutic candidate designed to prevent angioedema attacks in
Read More

Intellia Therapeutics Highlights Strategic Priorities and Anticipated 2023 Key Milestones

Strategic priorities focus on late-stage development of its CRISPR-based medicines while continuing to expand and validate its industry-leading genome editing platform Submit IND application in mid-2023 as part of a global pivotal study of NTLA-2001 for the treatment of transthyretin (ATTR)
Read More

Intellia Therapeutics Announces Pricing of Public Offering of Common Stock

CAMBRIDGE, Mass. , Nov. 30, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, announced today the pricing of an underwritten public offering
Read More

Intellia Therapeutics Announces Proposed Public Offering of Common Stock

CAMBRIDGE, Mass. , Nov. 30, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today announced that it has commenced an underwritten public
Read More
RSS FEEDS
PRINT PAGE